Biotech Investment News: Johnson & Johnson’s 10-Year Deal Summary & 2025 Update (2015–2025)
Strategic Review: Immunology, Oncology, and Rare Diseases at the Core of J&J’s R&D-Driven Vision Johnson & Johnson (J&J) has strategically expanded into immunology, oncology, and rare diseases by acquiring biotech compani...